Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia

Inclusion Criteria: * Patients must have a diagnosis of CLL according to National Cancer Institute (NCI) Working Group criteria * No prior treatment for CLL * Binet stage B or C * ECOG performance status ≤ 2 * Life expectancy ≥3 months * AST and ALT ≤ 3 x ULN; Total bilirubin ≤ 2 x ULN; Creatinine clearance ≥ 40 mL/min * Written informed consent Exclusion Criteria: * Patients were diagnosed with or treated for malignant tumors other than CLL (including central nervous system lymphoma) within one year prior to entering the study * Transformation to Richter's syndrome, or prolymphocytic leukemia (PLL) * Autoimmune hemolytic anemia requiring glucocorticoid therapy * Autoimmune thrombocytopenia requiring glucocorticoid therapy * Participation in any other clinical trials within 4 weeks prior to study entry * Any of the following conditions: severe heart failure; cardiomyopathy; myocardial infarction within 6 months; severe, uncontrolled diabetes; severe, uncontrolled hypertension; active, uncontrolled infection; central nervous system dysfunction * Patients received major surgery within 30 days prior to study entry * Pregnant or lactating women * Allergic to study drug or mannitol